{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:43:29Z","timestamp":1779245009258,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFE0131700"],"award-info":[{"award-number":["2022YFE0131700"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3602000"],"award-info":[{"award-number":["2022YFC3602000"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071813"],"award-info":[{"award-number":["82071813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271835"],"award-info":[{"award-number":["82271835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000639"],"award-info":[{"award-number":["32000639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Low-dose interleukin 2 (Ld-IL2) is increasingly being explored as an immune-modulating treatment for autoimmune diseases which mainly affect T cell subsets. This study investigates the metabolic effects of Ld-IL2 therapy in patients with primary Sj\u00f6gren\u2019s syndrome (pSS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A total of 60 patients were recruited to conduct a double-blind, randomized clinical trial. Of these patients, 50% (30\/60) received Ld-IL2 therapy along with standard treatment for 12 weeks, followed by 12 weeks of follow-up. The effectiveness was evaluated by Sj\u00f6gren's Tool for Assessing Response (STAR). An untargeted analysis was performed to profile hydrophilic metabolites.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Metabolic profiling revealed significant alterations post-treatment, notably in metabolites like acetyl-CoA, ascorbic acid, and glutathione, which are beneficial in managing autoimmune diseases. In addition, the levels of metabolite accumulation were correlated with variations in immune cell subsets (<jats:italic>p\u00a0<\/jats:italic>&lt; 0.05), particularly Tregs. Moreover, patients exhibiting a specific metabolic profile, including lower serum levels of isoleucine, ADP, Thymidine 5'-triphosphate, and other metabolites, had a high response rate (91.7%-98.6%), as indicated by the receiver operating characteristic (ROC) curve.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings suggest that Ld-IL2 therapy influences metabolic pathways in pSS, offering insights into the systemic effects of Ld-IL2 therapy beyond immune modulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>ClinicalTrials.gov number, NCT02464319.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022\u00a0<jats:italic>Metabolic alteration in pSS is significantly associated with Ld-IL2 therapy.<\/jats:italic>\u2022\u00a0<jats:italic>Metabolic changes correlate with variations in immune cell subsets, particularly Tregs.<\/jats:italic>\u2022\u00a0<jats:italic>Metabolic profiling could be a valuable tool in guiding Ld-IL2 therapy choices for pSS patients.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-024-07165-2","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T23:36:22Z","timestamp":1730417782000},"page":"3789-3798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic impact of low dose IL-2 therapy for primary Sj\u00f6gren\u2019s Syndrome in a double-blind, randomized clinical trial"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1465-3259","authenticated-orcid":false,"given":"Ruiling","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuebo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"issue":"1","key":"7165_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M et al (2020) Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 79(1):141\u20139","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7165_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang X, Miao M, Zhang R et al (2022) Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther 7(1):67","journal-title":"Signal Transduct Target Ther"},{"key":"7165_CR3","doi-asserted-by":"publisher","first-page":"105912","DOI":"10.1016\/j.intimp.2019.105912","volume":"77","author":"M Feng","year":"2019","unstructured":"Feng M, Guo H, Zhang C et al (2019) Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol 77:105912","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"7165_CR4","doi-asserted-by":"publisher","first-page":"e2241451","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He J, Chen J, Miao M et al (2022) Efficacy and safety of low-dose interleukin 2 for primary sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open 5(11):e2241451","journal-title":"JAMA Netw Open"},{"issue":"9","key":"7165_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y et al (2016) Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med 22(9):991\u20133","journal-title":"Nat Med"},{"issue":"1","key":"7165_CR6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41467-023-37424-w","volume":"14","author":"A Inaba","year":"2023","unstructured":"Inaba A, Tuong ZK, Zhao TX et al (2023) Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells. Nat Commun 14(1):2071","journal-title":"Nat Commun"},{"issue":"7","key":"7165_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.molmed.2022.04.010","volume":"28","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Kolios AGA, Liu Y et al (2022) Therapeutic potential of interleukin-2 in autoimmune diseases. Trends Mol Med 28(7):596\u2013612","journal-title":"Trends Mol Med"},{"issue":"4","key":"7165_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/rai2.12047","volume":"2","author":"M Xue","year":"2022","unstructured":"Xue M, Feng J, Yang A et al (2022) Th17\/Treg balance and factors related to autoimmune hepatitis. Rheumatology & Autoimmunity 2(4):221\u20139","journal-title":"Rheumatology & Autoimmunity"},{"issue":"4","key":"7165_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck MD, Sowell RT, Kaech SM, Pearce EL (2017) Metabolic Instruction of Immunity. Cell 169(4):570\u201386","journal-title":"Cell"},{"issue":"1","key":"7165_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","volume":"55","author":"NM Chapman","year":"2022","unstructured":"Chapman NM, Chi H (2022) Metabolic adaptation of lymphocytes in immunity and disease. Immunity 55(1):14\u201330","journal-title":"Immunity"},{"issue":"6387","key":"7165_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg MD, Bhargava P, Kim PM et al (2018) Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 360(6387):449\u201353","journal-title":"Science"},{"issue":"7","key":"7165_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/cr.2015.68","volume":"25","author":"B Kelly","year":"2015","unstructured":"Kelly B, O\u2019Neill LA (2015) Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res 25(7):771\u201384","journal-title":"Cell Res"},{"issue":"6311","key":"7165_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.aaf6284","volume":"354","author":"M Peng","year":"2016","unstructured":"Peng M, Yin N, Chhangawala S, Xu K, Leslie CS, Li MO (2016) Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354(6311):481\u20134","journal-title":"Science"},{"issue":"5","key":"7165_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s42255-022-00575-z","volume":"4","author":"Q Liu","year":"2022","unstructured":"Liu Q, Zhu F, Liu X et al (2022) Non-oxidative pentose phosphate pathway controls regulatory T cell function by integrating metabolism and epigenetics. Nat Metab 4(5):559\u201374","journal-title":"Nat Metab"},{"key":"7165_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fimmu.2019.00115","volume":"10","author":"D Cluxton","year":"2019","unstructured":"Cluxton D, Petrasca A, Moran B, Fletcher JM (2019) Differential Regulation of Human Treg and Th17 Cells by Fatty Acid Synthesis and Glycolysis. Front Immunol 10:115","journal-title":"Front Immunol"},{"issue":"1","key":"7165_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-022-01103-x","volume":"7","author":"F Xiao","year":"2022","unstructured":"Xiao F, Rui K, Han M et al (2022) Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog\u0308ren\u2019s syndrome. Signal Transduct Target Ther 7(1):274","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"7165_CR17","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1007\/s00018-021-03978-5","volume":"78","author":"S Umar","year":"2021","unstructured":"Umar S, Palasiewicz K, Volin MV et al (2021) Metabolic regulation of RA macrophages is distinct from RA fibroblasts and blockade of glycolysis alleviates inflammatory phenotype in both cell types. Cell Mol Life Sci 78(23):7693\u2013707","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"7165_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror R, Baron G, Camus M et al (2022) Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 81(7):979\u201389","journal-title":"Ann Rheum Dis"},{"key":"7165_CR19","doi-asserted-by":"publisher","first-page":"109818","DOI":"10.1016\/j.clim.2023.109818","volume":"257","author":"C Wang","year":"2023","unstructured":"Wang C, Wang Y, Wang F et al (2023) High intestinal isoleucine is a potential risk factor for food allergy by regulating the mTOR\/AKT pathway in dendritic cells. Clin Immunol 257:109818","journal-title":"Clin Immunol"},{"issue":"7508","key":"7165_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nature13312","volume":"511","author":"B Ghesqui\u00e8re","year":"2014","unstructured":"Ghesqui\u00e8re B, Wong BW, Kuchnio A, Carmeliet P (2014) Metabolism of stromal and immune cells in health and disease. Nature 511(7508):167\u201376","journal-title":"Nature"},{"key":"7165_CR21","doi-asserted-by":"crossref","unstructured":"Sardar SW, Nam J, Kim TE, Kim H, Park YH. Identification of Novel Biomarkers for Early Diagnosis of Atherosclerosis Using High-Resolution Metabolomics. Metabolites 2023:13(11)","DOI":"10.3390\/metabo13111160"},{"key":"7165_CR22","doi-asserted-by":"crossref","unstructured":"Birkner K, Wasser B, Ruck T et al (2020) \u03b21-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells. J Clin Invest 130(2):715\u201332","DOI":"10.1172\/JCI126381"},{"issue":"7666","key":"7165_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature23475","volume":"548","author":"T Xu","year":"2017","unstructured":"Xu T, Stewart KM, Wang X et al (2017) Metabolic control of T(H)17 and induced T(reg) cell balance by an epigenetic mechanism. Nature 548(7666):228\u201333","journal-title":"Nature"},{"key":"7165_CR24","doi-asserted-by":"publisher","first-page":"1400063","DOI":"10.3389\/fnut.2024.1400063","volume":"11","author":"L Jiang","year":"2024","unstructured":"Jiang L, Song C, Ai C, Wen C, Song S (2024) Modulation effect of sulfated polysaccharide from Sargassum fusiforme on gut microbiota and their metabolites in vitro fermentation. Front Nutr 11:1400063","journal-title":"Front Nutr"},{"issue":"6","key":"7165_CR25","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/ptr.7462","volume":"36","author":"L Cheng","year":"2022","unstructured":"Cheng L, Shi L, He C et al (2022) Rutin-activated adipose tissue thermogenesis is correlated with increased intestinal short-chain fatty acid levels. Phytother Res 36(6):2495\u2013510","journal-title":"Phytother Res"},{"issue":"6","key":"7165_CR26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","volume":"153","author":"CH Chang","year":"2013","unstructured":"Chang CH, Curtis JD, Maggi LB Jr et al (2013) Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153(6):1239\u201351","journal-title":"Cell"},{"issue":"1","key":"7165_CR27","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1038\/s41467-019-13078-5","volume":"10","author":"ST Liao","year":"2019","unstructured":"Liao ST, Han C, Xu DQ, Fu XW, Wang JS, Kong LY (2019) 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects. Nat Commun 10(1):5091","journal-title":"Nat Commun"},{"issue":"6","key":"7165_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","volume":"21","author":"F Pietrocola","year":"2015","unstructured":"Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G (2015) Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab 21(6):805\u201321","journal-title":"Cell Metab"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07165-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:05:38Z","timestamp":1732187138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07165-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7165"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07165-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Human Ethics Committee of Peking University People\u2019s Hospital (Beijing, China) (2020PHB359-01). Participants gave informed consent to participate in the study before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statements"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}